InterMune Announces Proposed Concurrent Public Offerings Of Common Stock And Convertible Debt

 InterMune Announces Proposed Concurrent Public Offerings Of Common Stock And
                               Convertible Debt

PR Newswire

BRISBANE, Calif., Jan. 14, 2013

BRISBANE, Calif., Jan. 14, 2013 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN)
today announced that it plans to offer, subject to market and other
conditions, $85.0 million aggregate principal amount of convertible senior
notes due 2017 and 12,500,000 shares of its common stock in concurrent
underwritten public offerings. InterMune expects to grant the underwriters
30-day options to purchase up to an additional $12.75 million aggregate
principal amount of convertible senior notes and up to an additional 1,875,000
shares of common stock in connection with the offerings. 


InterMune intends to use the net proceeds from both offerings to repay at
maturity or earlier repurchase InterMune's outstanding 5.00% convertible
senior notes due 2015, as well as to fund the commercialization of EsbrietĀ®
(pirfenidone), to fund InterMune's ASCEND trial and for general corporate
purposes, which may include funding research and development, and working
capital. InterMune may also use a portion of the net proceeds for capital
expenditures or for acquisitions or investments in complementary businesses,
products and technologies. 

Goldman, Sachs& Co. and J. P. Morgan Securities LLC are acting as joint
book-running managers of these proposed offerings. The common stock offering
and the convertible senior note offering will be conducted as separate public
offerings by means of separate prospectus supplements filed as part of an
effective shelf registration statement filed with the Securities and Exchange
Commission (SEC) on Form S-3. Neither of these offerings is contingent upon
the consummation of the other. Before investing in either offering,
interested parties may read the prospectus supplement and the accompanying
prospectus for such offering and the other documents InterMune has filed with
the SEC, which are incorporated by reference in the prospectus supplements and
the accompanying prospectus and provide more complete information about
InterMune and the offerings. Copies of the preliminary prospectus supplements
and the accompanying prospectus relating to each offering may be obtained,
when available, from Goldman, Sachs& Co. (Attn: Prospectus Department, 200
West Street, New York, New York 10282, Fax: 212-902-9316 or Email at or by calling 1-866-471-2526) or J.P. Morgan
Securities LLC (c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717 or by calling 866-803-9204). Electronic copies of the
prospectus supplements may be obtained by visiting EDGAR on the SEC's website

This announcement does not constitute an offer to sell or a solicitation of an
offer to buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state
or jurisdiction. This press release is being issued pursuant to and in
accordance with Rule 134 under the Securities Act of 1933, as amended. Any
offer, if at all, will be made only by means of a prospectus supplement and
the accompanying prospectus, forming a part of the effective registration

About InterMune
InterMune is a biotechnology company focused on the research, development and
commercialization of innovative therapies in pulmonology and fibrotic

Forward-Looking Statements
This announcement contains forward-looking statements, including statements
relating to InterMune's expectations regarding the completion, timing and size
of the proposed public offerings. These statements are subject to significant
risks and uncertainties, actual results could differ materially from those
projected and InterMune cautions investors not to place undue reliance on the
forward-looking statements contained in this release. These risks and
uncertainties include, without limitation, risks and uncertainties related to
market conditions and satisfaction of customary closing conditions related to
the public offerings. There can be no assurance that InterMune will be able
to complete either one or both of the public offerings on the anticipated
terms, or at all. If InterMune is unable to raise additional capital when
required or on acceptable terms, it may have to significantly delay, scale
back or discontinue one or more of its drug development or discovery research
programs. Additional risks and uncertainties relating to InterMune and its
business can be found in the "Risk Factors" section of InterMune's Form 10-K
filed with the SEC and quarterly reports on Form 10-Q, and in the prospectus
supplements related to the proposed offerings to be filed with the SEC.
InterMune undertakes no duty or obligation to update any forward-looking
statements contained in this release as a result of new information, future
events or changes in InterMune's expectations.

SOURCE InterMune, Inc.

Contact: Jim Goff, InterMune, Inc., +1-415-466-2228,
Press spacebar to pause and continue. Press esc to stop.